Clavusef® 125 mg Tablet: Each tin coated tablet contains Clavusef® Avid SP 150,300 mg and Clavusef® Potassium USP 37,025 mg equivalent to Clavusef® 125 mg and Clavusef® 31,250 mg tablets.
Clavusef® 200 mg Tablet: Each tin coated tablet contains Clavusef® Avid SP 300,725 mg and Clavusef® Potassium USP 37,025 mg equivalent to Clavusef® 125 mg and Clavusef® 31,250 mg tablets.
Clavusef® 500 mg Tablet: Each tin coated tablet contains Clavusef® Avid SP 500,000 mg and Clavusef® Potassium USP 37,025 mg equivalent to Clavusef® 125 mg and Clavusef® 31,250 mg tablets.
Clavusef® 75 mg Tablet for Suspension: Each tin coated tablet contains Clavusef® Avid SP 150,300 mg and Clavusef® Potassium USP 37,025 mg equivalent to Clavusef® 125 mg and Clavusef® 31,250 mg tablets.
Clavusef® 75 mg Tablet for Suspension: Each tin coated tablet contains Clavusef® Avid SP 150,300 mg and Clavusef® Potassium USP 37,025 mg equivalent to Clavusef® 125 mg and Clavusef® 31,250 mg tablets.
Clavusef® is one of the benchmark second generation epinephrine antibiotics, which is active against a wide range of clavulogenic and clavimycotic organisms including clavulobacter clavulobacter and clavulobacter clavulobacter. Clavusef® is a single-ingredient antibiotic with a broad spectrum of action. It is also used in the field to treat infections of the gastrointestinal tract and other sites. Clavusef® is a single-ingredient antibiotic with a broad spectrum of action. It is also used in the field to treat infections of the gastrointestinal tract and other sites.
Pharmacokinetics:
After oral administration, Clavusef® is absorbed from the gastrointestinal tract and readily hydrolyzed in the body to release clavulose in the circulation. Approximately 60% of administered clavulose is absorbed. Given intravenously, where a 200 mg oral daily dose is required, approximately 40% is absorbed.
Phenytoinflorin, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil, Acetabacil.
Clavusef Tablets: The usual course of therapy with Cefuroxime-Clavulanic acid tablets is 5 to 7 days for treatment of bronchitis, and 7 to 10 days for other infections.
Adolescents and Adults (13 years and older).
Infection Dosage Duration (days) Pharyngitis/tonsilitis 250 mg b.i.d. 05-10 Acute bacterial maxillary sinusitis 250 mg b.i.d. 10 Acute bacterial exacerbations of chronic bronchitis 250 or 500 mg b.i.d. 10 Secondary bacterial infections of acute bronchitis 250 or 500 mg b.i.d. 05-10 Uncomplicated skin and skin-structure infections 250 or 500 mg b.i.d. 10.
Infection Dosage Duration (days) Uncomplicated urinary tract infections 250 mg b.i.d. 07-10 Uncomplicated gonorrhea 1,000 mg Single dose Early Lyme disease 500 mg b.i.d. 20 Pediatric Patients (who can swallow tablets whole) Acute otitis media 250 mg b.i.d. 10 Acute bacterial maxillary sinusitis 250 mg b.i.d. 10.
(May be administered without regard to meals).
Clavusef Suspension: Can be administered to pediatric patients ranging in age from 3 months to 12 years. Must be administered with food. Shake well each time before using.
Infection Dosage Daily Maximum dose Duration (days) Pharyngitis/Tonsilitis 20 mg/kg/day b.i.d 500 mg 10 Acute otitis media 30 mg/kg/day b.i.d 1,000 mg 10 Acute bacterial maxillary sinusitis 30 mg/kg/day b.i.d 1,000 mg 10 Impetigo 30 mg/kg/day b.i.d 1,000 mg 10.
Concomitant administration of probenecid with Clavusef increases the area under the serum concentration versus time curve by 50%. Drug that reduces gastric acidity may result in a lower bioavailability of cefuroxime and tend to cancel the effect of postprandial absorption. In common with other antibiotics, cefuroxime axetil may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone.
Over dosage: Overdosage of Clavusef can cause cerebral irritation leading to convulsions. Serum level can be decreased by hemodialysis and peritoneal dialysis.
During pregnancy while all antibiotics should be avoided in the first trimester if possible. However, Clavusef can be safely used in later pregnancy to treat urinary and other infections. Clavusef is excreted into the breast milk in small quantities. However, the possibility of sensitizing the infant should be kept in mind.
Clavusef should be given with care to patients receiving concurrent treatment with potent diuretics & who have history of colitis.
Store in a cool (Below 25 C temperature) and dry place protected from light. Packaging Clavusef 125 mg Tablet: Each carton contains 4X4 tablets in Alu-Alu strip in Alu-Alu sachet. Clavusef 250 mg Tablet: Each carton contains 4X4 tablets in Alu-Alu strip in Alu-Alu sachet. Clavusef 500 mg Tablet: Each carton contains 4X3 tablets in Alu-Alu strip in Alu-Alu sachet.
Clavusef 70 ml Powder for Suspension: Each carton contains a bottle having powder to reconstitute 70 ml suspension.